CG Oncology Stock (NASDAQ:CGON)

Forecast Revenue Ownership Financials Chart

Previous Close

$62.97

52W Range

$14.80 - $64.67

50D Avg

$53.72

200D Avg

$38.71

Market Cap

$5.43B

Avg Vol (3M)

$1.19M

Beta

1.19

Div Yield

-

CGON Company Profile

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

113

IPO Date

Jan 25, 2024

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25
License And Collaboration Revenue	$806.00K

Fiscal year ends in Dec 25 | Currency in USD

CGON Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$4.04M	$1.14M	$204.00K
Operating Income	$-190.77M	$-114.67M	$-55.45M
Net Income	$-161.00M	$-88.04M	$-48.61M
EBITDA	$-159.55M	$-114.63M	$-55.43M
Basic EPS	$-2.08	$-1.41	$-1.02
Diluted EPS	$-2.08	$-1.41	$-1.02

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IRON	Disc Medicine, Inc.
AAPG	ASCENTAGE PHARMA GROUP INTERNATIONAL
TARS	Tarsus Pharmaceuticals, Inc.
TVTX	Travere Therapeutics, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
CELC	Celcuity Inc.
XENE	Xenon Pharmaceuticals Inc.
LEGN	Legend Biotech Corporation
CNTA	Centessa Pharmaceuticals plc
APGE	Apogee Therapeutics, Inc.